By
Statens Serum Institut
Published: Feb. 7, 2016, 6:14 p.m.·
Tags:
Vaccines
Due to production issues and rehabilitation of the BCG production line at Statens Serum Institut (SSI), the SSI’s BCG vaccine against tuberculosis has been on back order for a substantial period of time, and the current outlook is that the SSI will remain unable to provide the vaccine at least until the end of 2016. Furthermore, there is a general lack of BCG vaccine on the world market, including in countries which have included the vaccine into their childhood vaccination programme.
Read More →
By
Statens Serum Institut
Published: Nov. 8, 2013, 1:23 p.m.·
Tags:
None
Statens Serum Institut (SSI) and Aeras today announced the initiation of a Phase I/IIa clinical trial for a candidate tuberculosis (TB) vaccine designed to protect people, especially those latently infected with TB, from developing active TB disease.
Read More →